Herborium Group Inc (HBRM)

[resx18]

$HBRM offers a unique combination of products and content in the natural skincare sector. Presently focused on acne treatment and prevention the company tests its natural formulations with the same standards found in the pharmaceutical industry creating higher efficacy, proven safety, and consumer satisfaction.

The company is now set to roll out an AI technology platform that will allow its consumers to diagnose the products they need utilizing the company’s proprietary skin diagnostic software. HBRM’s SKIN-NATURA is a curated platform providing integrated, natural, safe, and efficacious products and treatment regimens. This is complemented by support content and personalized know-how focused on skin health and beauty (in the field of dermatology, nutrition, and cosmetology). The platform is driven by AI-based technology to streamline both the diagnostic and deliverables. This allows for seamless integration of the most desirable products and content provided by the company and the NATURA Consortium. Consumers benefit from a comprehensive solution to their needs, delivered in an expedient and user-friendly manner, and at the optimal price point. Herborium will realize multiple revenue streams and brand-building benefits from this program. Consortium partners benefit from cooperative marketing power, innovative technology to interact with consumers, and the Skin Natura brand and expertise.

Many companies claim they have natural products for skin problems. The issue is the ‘natural’ buzzword is being used without accountability for efficacy or quality. This is where HBRM shines, the company is a legacy ‘natural’ care company with high-quality efficacy and safety standards, for its own Botanical Therapeutics the Company uses clinical validation and a proactive regulatory strategy based on the FDA’s Botanical Drug Development Guidance for Industry, 2016 to establish and maintain a differential market advantage. Herborium harvests its proprietary therapeutic candidates from Traditional Chinese Medicine with initial confirmatory data and utilizes Western regulatory, clinical, and marketing strategies to successfully introduce the products to the Western markets. This strategy serves to mitigate risk in product development and fortifies marketing strategies.